Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

On Friday, Immunic Inc (IMUX) stock saw a decline, ending the day at $1.19 which represents a decrease of $-0.02 or -1.65% from the prior close of $1.21. The stock opened at $1.21 and touched a low of ...

Leerink Partners has recently resumed Immunic Inc (IMUX) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on August 27, 2024, B. Riley Securities had ...

Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to ...

Looking for cheap stocks (by price, at least)? Find U.S.-listed stocks with a price tag under $10 a share, listed by trailing one-year split-adjusted returns. Prices and return data are based on the ...

Take a look at six multiple sclerosis companies trying to make a difference to patients by advancing new treatments for the ...

A pair of Phase 3 trials testing vidofludimus calcium in relapsing MS are continuing as planned after a positive committee ...

July 24, 2024 — Scientists have discovered that the serrated edges of Komodo dragons' teeth are tipped with iron. The study gives new insight into how Komodo dragons keep their teeth razor-sharp ...

It’s a go for the two phase III Ensure studies of Immunic Inc.’s lead asset in treating relapsing multiple sclerosis. An ...

NEW YORK - Immunic, Inc. (NASDAQ: NASDAQ:IMUX), a biotechnology firm focused on treatments for chronic inflammatory and autoimmune diseases, announced today that its phase 3 ENSURE program for the ...

Immunic (IMUX) stock fell after the company said it plans to continue its Phase 3 ENSURE program for lead drug IMU-838 in ...